相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular Risk - Primary Results From the Phase 2 YUKAWA Study
Atsushi Hirayama et al.
CIRCULATION JOURNAL (2014)
APOE*3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome
A. M. van den Hoek et al.
DIABETES OBESITY & METABOLISM (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
My-Anh Nguyen et al.
JOURNAL OF LIPID RESEARCH (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Anti-PCSK9 Monotherapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1
Cedric Le May et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
APOE p.Leu167del mutation in familial hypercholesterolemia
Zuhier Awan et al.
ATHEROSCLEROSIS (2013)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2013)
Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor: Evidence for a Reciprocal Regulation
Hagai Tavori et al.
CIRCULATION (2013)
Anti-PCSK9 therapies for the treatment of hypercholesterolemia
Amanda J. Hooper et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport
Li Shen et al.
FEBS LETTERS (2013)
Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation
Marie Marduel et al.
HUMAN MUTATION (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Maxime Denis et al.
CIRCULATION (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOEM*3Leiden.CETP transgenic mice with or without treatment with atorvastatin
Susan Kuhnast et al.
JOURNAL OF HYPERTENSION (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates
Hong Liang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
Fen Du et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
Bronwen Herbert et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
Yan G. Ni et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
The LDL Receptor
Joseph L. Goldstein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
Christopher J. Duff et al.
BIOCHEMICAL JOURNAL (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Jose W. A. van der Hoorn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Self-association of human PCSK9 correlates with its LDLR-degrading activity
Daping Fan et al.
BIOCHEMISTRY (2008)
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
Willeke de Haan et al.
CIRCULATION (2008)
Molecular basis for LDL receptor recognition by PCSK9
Hyock Joo Kwon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice
Jose W. A. van der Hoorn et al.
JOURNAL OF HYPERTENSION (2007)
Mouse models for atherosclerosis and pharmaceutical modifiers
Susanne Zadelaar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression
Caroline C. van der Hoogt et al.
JOURNAL OF LIPID RESEARCH (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE* 3-Leiden mice
Marit Westerterp et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Fenofibrate reduces atherogenesis in ApoE*3Leiden mice - Evidence for multiple antiatherogenic effects besides lowering plasma cholesterol
T. Kooistra et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene - Long-term follow-up and treatment response
RP Naoumova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Role of cholesterol and lipid organization in disease
FR Maxfield et al.
NATURE (2005)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice
SMSE Santo et al.
JOURNAL OF LIPID RESEARCH (2005)
Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia
XM Sun et al.
HUMAN MOLECULAR GENETICS (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans
D Steinberg
JOURNAL OF LIPID RESEARCH (2005)
An interpretive history of the cholesterol controversy: part I
D Steinberg
JOURNAL OF LIPID RESEARCH (2004)
Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia
H Gylling
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice - Evidence for antiinflammatory effects of rosuvastatin
R Kleemann et al.
CIRCULATION (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Acyl-CoA: Cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice
DJM Delsing et al.
CIRCULATION (2001)